Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) traded at $14.43 at last check on Friday, Nov 20, making an upward move of 7.29% on its previous day’s price.
Looking at the stock we see that its previous close was $13.45 and the beta (5Y monthly) reads 0 with the day’s price range being $13.50 – 14.75. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, AUPH has a high of $21.93 and a low of $5.74. The company’s stock has gained about -5% over that past 30 days.
Aurinia has a market cap of $1.82 Billion and is expected to release its quarterly earnings report in Aug. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the AUPH stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$0.14, with the EPS growth for the year declined at -$1.01 for 2020 and -$0.55 for next year. These figures represent 0.53% and at -0.46% growth in EPS for the two years respectively.
On the other hand, looking at the outlook for the AUPH stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 50% Sell. Long term indicators on average place the stock in the category of 100% Sell.
Let’s briefly compare Aurinia (AUPH) stock to its peers. We find that today’s price change of +7.29% and +131.62% over the past 12 months for AUPH betters that of Zoetis Inc Cl A (ZTS), which has seen its stock price fall -0.07% in the latest trading session and is +38.25% over the last one year. Another of its peers Takeda Pharmaceutical CO Ltd (TAK) has climbed 0.57% today, but is -14.39% down over the past year, while Catalent Inc (CTLT) is also up 7.29% yet its price remains in the green at 131.62% over the same period. Zoetis has a P/E ratio of 47.72 compared to Aurinia’s 0 and Takeda’s 21.63. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at -0.68% and -0.75%, respectively, in early deals.
Coming back to Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), we note that the average 3-month trading volume was 1.03 Million, while that of the preceding 10-day period stands at 1.22 Million. Current shares outstanding are 126.25 Million.
According to data from Thomson Reuters, insiders hold 13.78% of the company’s shares while institutions hold 55.72%. The data shows that short shares as of October 29, 2020, stood at 4.25 Million at a short ratio of 5.43. This represents a 3.36% Short interest in Shares outstanding on October 29, 2020. Shares short rose in October from the previous month at 4.18 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -28.78% down in year-to-date price movement.